These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11274206)

  • 1. Formation of a stable heterodimer between Smad2 and Smad4.
    Wu JW; Fairman R; Penry J; Shi Y
    J Biol Chem; 2001 Jun; 276(23):20688-94. PubMed ID: 11274206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells.
    De Bosscher K; Hill CS; Nicolás FJ
    Biochem J; 2004 Apr; 379(Pt 1):209-16. PubMed ID: 14715079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
    Xu J; Attisano L
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4820-5. PubMed ID: 10781087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling.
    Souchelnytskyi S; Tamaki K; Engström U; Wernstedt C; ten Dijke P; Heldin CH
    J Biol Chem; 1997 Oct; 272(44):28107-15. PubMed ID: 9346966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
    Kuang C; Chen Y
    Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.
    Kawabata M; Inoue H; Hanyu A; Imamura T; Miyazono K
    EMBO J; 1998 Jul; 17(14):4056-65. PubMed ID: 9670020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of phosphorylated-Smad2-containing complexes by a novel Smad interaction motif.
    Randall RA; Howell M; Page CS; Daly A; Bates PA; Hill CS
    Mol Cell Biol; 2004 Feb; 24(3):1106-21. PubMed ID: 14729957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
    Poncelet AC; de Caestecker MP; Schnaper HW
    Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway.
    Jayaraman L; Massague J
    J Biol Chem; 2000 Dec; 275(52):40710-7. PubMed ID: 11018029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of Smad2 recognition by the Smad anchor for receptor activation.
    Wu G; Chen YG; Ozdamar B; Gyuricza CA; Chong PA; Wrana JL; Massagué J; Shi Y
    Science; 2000 Jan; 287(5450):92-7. PubMed ID: 10615055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of constitutively active Smad2 mutants: evaluation of formation of Smad complex and subcellular distribution.
    Funaba M; Mathews LS
    Mol Endocrinol; 2000 Oct; 14(10):1583-91. PubMed ID: 11043574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling.
    Itoh S; Ericsson J; Nishikawa J; Heldin CH; ten Dijke P
    Nucleic Acids Res; 2000 Nov; 28(21):4291-8. PubMed ID: 11058129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor.
    Ulloa L; Tabibzadeh S
    J Biol Chem; 2001 Jun; 276(24):21397-404. PubMed ID: 11278746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation.
    Prunier C; Pessah M; Ferrand N; Seo SR; Howe P; Atfi A
    J Biol Chem; 2003 Jul; 278(28):26249-57. PubMed ID: 12732634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta.
    Feng XH; Lin X; Derynck R
    EMBO J; 2000 Oct; 19(19):5178-93. PubMed ID: 11013220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.
    Wu JW; Hu M; Chai J; Seoane J; Huse M; Li C; Rigotti DJ; Kyin S; Muir TW; Fairman R; Massagué J; Shi Y
    Mol Cell; 2001 Dec; 8(6):1277-89. PubMed ID: 11779503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells.
    Runyan CE; Schnaper HW; Poncelet AC
    J Biol Chem; 2005 Mar; 280(9):8300-8. PubMed ID: 15613484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes.
    Liu F; Pouponnot C; Massagué J
    Genes Dev; 1997 Dec; 11(23):3157-67. PubMed ID: 9389648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential ubiquitination defines the functional status of the tumor suppressor Smad4.
    Morén A; Hellman U; Inada Y; Imamura T; Heldin CH; Moustakas A
    J Biol Chem; 2003 Aug; 278(35):33571-82. PubMed ID: 12794086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain.
    de Caestecker MP; Yahata T; Wang D; Parks WT; Huang S; Hill CS; Shioda T; Roberts AB; Lechleider RJ
    J Biol Chem; 2000 Jan; 275(3):2115-22. PubMed ID: 10636916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.